Table 1 Characteristics of 13 studies for the present pooled analysis.
Dossaa | Polancoa | Song | Xua | Shahaba | Kuan | Lorenzon | Gamaleldin | Tay | Kim | Lichthardt | Maas | Geva | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Source of data | NCDB | NCDB | Seoul Univ Bundang | NCDB | NCDB | TCRD | Multi-institutional | Cleveland | ACCORD | Yonsei | Wuerzburg | Multi-institutional | Tel Aviv |
Country | USA | USA | Korea | USA | USA | Taiwan | Italy/Spain | USA | Australia | Korea | Germany | Multi-national | Israel |
Year of publication | 2018 | 2018 | 2018 | 2017 | 2017 | 2017 | 2017 | 2017 | 2017 | 2017 | 2017 | 2015 | 2014 |
Study period | 2006–2012 | 2006–2012 | 2004–2015 | 2006–2011 | 2006–2013 | 2007–2013 | 2005–2015 | 2000–2012 | 2003–2014 | 2001–2013 | 1992–2013 | Variable | 2001–2013 |
Data adjustment | Yes | Yes | No | Yes | Yes | Yes | No | No | No | Yes | No | Yes | No |
No. of pCR patients (ACT/No ACT) | 1334 (667/667) | 1482 (741/741) | 50 (43/7) | 1727 (484/1243) | 2891 (789/2102) | 259b (114/145) | 232 (77/155) | 130c (47/83) | 126 (97/29) | 77 (37/40) | 24 (9/15) | 898 (290/608) | 52 (35/17) |
Proportion of CRT(%) | 100 | 100 | 100 | 100 | 100 | 100 | NAd | 100 | 100 | 100 | NAe | 100 | 100 |
CRT-Op interval | 5–12 weeks for 84% | NA | Median 46.5 weeks (36–76) | NA | NA | <6/6–8/>8 weeks for 21%/46%/33% | Median 9 weeks (3–25) | NA | Median 6.9 weeks | 4–8 weeks | NA | Generally 6–8 weeks | 5.7–13.6 weeks |
RT dose | 45–54 Gy for 76% | NA | 50.4 Gy | NA | NA | 40–51 Gy for 93% | Median 50.4 Gy (50.4–56) for long-course CRT, short-course RT (9%) included | Median 50.4 Gy | Median 50 Gy | 45–50.4 Gy | NA | 45–50.4 Gy | Median 50.4 Gy (45–50.4) |
ACT regimen | NA | NA | 5-FU based (including FL, capecita-bine, FOLFOX) | NA | NA | 5-FU-based (including FL, tegafur or capecita-bine) | Oral/i.v. fluoro-pyrimidine | 5-FU or FLf | Fluoro-pyrimidineg | FL, capecita-bine | 5-FU, capecita-bine, FOLFOX/ FOLFIRI | Fluoro-pyrimidine-based | 5-FU, capecita-bine |
Types of surgery | NAh | Partial/total proc-tectomy for 61%/24% | LAR or U-LAR | NA | Partial/total proc-tectomy for 71%/28% | LAR/APR for 72%/12% | LAR/APR for 75%/16% | Total mesorectal excision | NA | LAR/APR | Total mesorectal excision | LAR/APR for 76%/22% | LAR/APR for 69%/31% |
